Second hematopoietic stem cell transplantation with a new haploid-mismatched donor in relapsed patients after first transplantation: prognostic analysis of 11 cases

Objective To investigate the clinical outcome of the patients with hematologic malignancy recurrence following first allogenetic hematopoietic stem cell transplantation (allo-HSCT) and receiving second transplantation from an alternative haploid-mismatched donor. Methods We retrospectively reported...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	ZHU Panpan, WU Yibo, LIU Lizhen, LAI Xiaoyu, SHI Jimin
Formato:	article
Lenguaje:	ZH
Publicado:	Editorial Office of Journal of Third Military Medical University 2021
Materias:	second stem cell transplantation donor lymphocyte infusion hematologic malignancies relapse Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/61403dfc44dd43edb652dc670c73e729
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:61403dfc44dd43edb652dc670c73e729
record_format	dspace
spelling	oai:doaj.org-article:61403dfc44dd43edb652dc670c73e7292021-11-12T04:34:53ZSecond hematopoietic stem cell transplantation with a new haploid-mismatched donor in relapsed patients after first transplantation: prognostic analysis of 11 cases10.16016/j.1000-5404.2021080911000-5404https://doaj.org/article/61403dfc44dd43edb652dc670c73e7292021-11-01T00:00:00Zhttp://aammt.tmmu.edu.cn/Upload/rhtml/202108091.htmhttps://doaj.org/toc/1000-5404Objective To investigate the clinical outcome of the patients with hematologic malignancy recurrence following first allogenetic hematopoietic stem cell transplantation (allo-HSCT) and receiving second transplantation from an alternative haploid-mismatched donor. Methods We retrospectively reported the clinical data of 11 patients with hematologic malignancies who underwent a second HSCT using a new haploidentical related donor (HRD) in our center between October 2013 and June 2021. At the second transplantation, all patients were in complete remission (CR). Six of them received donor lymphocyte infusion (DLI) after the second transplantation. The clinical prognosis of the patients was followed up to primarily explore the effect of secondary transplantation. Results The median follow-up was 9.4 (2.9~94.9) months. Of the 11 relapsed patients, 3 patients died of disease relapse and 1 patient died of lung infection, and the remaining 7 patients survived with CR. The 1-year overall survival (OS) rate was 77.9% (95%CI: 54.6%~ 99.9%), so was 1-year leukemia-free survival (LFS) rate. For the 6 patients receiving DLI, the 1-year OS rate was 83.3% (95%CI: 58.3%~99.9%). The cumulative incidence of relapse was 22.1% in the 11 patients. Conclusion A second HSCT using a new haploid-mismatched donor is a feasible strategy for the patients with hematologic malignancy recurrence after the first transplantation. It has no significant increase in treatment-related death, and shows a certain safety.ZHU PanpanWU YiboLIU LizhenLAI XiaoyuSHI JiminEditorial Office of Journal of Third Military Medical Universityarticlesecond stem cell transplantationdonor lymphocyte infusionhematologic malignanciesrelapseMedicine (General)R5-920ZHDi-san junyi daxue xuebao, Vol 43, Iss 21, Pp 2294-2301 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	second stem cell transplantation donor lymphocyte infusion hematologic malignancies relapse Medicine (General) R5-920
spellingShingle	second stem cell transplantation donor lymphocyte infusion hematologic malignancies relapse Medicine (General) R5-920 ZHU Panpan WU Yibo LIU Lizhen LAI Xiaoyu SHI Jimin Second hematopoietic stem cell transplantation with a new haploid-mismatched donor in relapsed patients after first transplantation: prognostic analysis of 11 cases
description	Objective To investigate the clinical outcome of the patients with hematologic malignancy recurrence following first allogenetic hematopoietic stem cell transplantation (allo-HSCT) and receiving second transplantation from an alternative haploid-mismatched donor. Methods We retrospectively reported the clinical data of 11 patients with hematologic malignancies who underwent a second HSCT using a new haploidentical related donor (HRD) in our center between October 2013 and June 2021. At the second transplantation, all patients were in complete remission (CR). Six of them received donor lymphocyte infusion (DLI) after the second transplantation. The clinical prognosis of the patients was followed up to primarily explore the effect of secondary transplantation. Results The median follow-up was 9.4 (2.9~94.9) months. Of the 11 relapsed patients, 3 patients died of disease relapse and 1 patient died of lung infection, and the remaining 7 patients survived with CR. The 1-year overall survival (OS) rate was 77.9% (95%CI: 54.6%~ 99.9%), so was 1-year leukemia-free survival (LFS) rate. For the 6 patients receiving DLI, the 1-year OS rate was 83.3% (95%CI: 58.3%~99.9%). The cumulative incidence of relapse was 22.1% in the 11 patients. Conclusion A second HSCT using a new haploid-mismatched donor is a feasible strategy for the patients with hematologic malignancy recurrence after the first transplantation. It has no significant increase in treatment-related death, and shows a certain safety.
format	article
author	ZHU Panpan WU Yibo LIU Lizhen LAI Xiaoyu SHI Jimin
author_facet	ZHU Panpan WU Yibo LIU Lizhen LAI Xiaoyu SHI Jimin
author_sort	ZHU Panpan
title	Second hematopoietic stem cell transplantation with a new haploid-mismatched donor in relapsed patients after first transplantation: prognostic analysis of 11 cases
title_short	Second hematopoietic stem cell transplantation with a new haploid-mismatched donor in relapsed patients after first transplantation: prognostic analysis of 11 cases
title_full	Second hematopoietic stem cell transplantation with a new haploid-mismatched donor in relapsed patients after first transplantation: prognostic analysis of 11 cases
title_fullStr	Second hematopoietic stem cell transplantation with a new haploid-mismatched donor in relapsed patients after first transplantation: prognostic analysis of 11 cases
title_full_unstemmed	Second hematopoietic stem cell transplantation with a new haploid-mismatched donor in relapsed patients after first transplantation: prognostic analysis of 11 cases
title_sort	second hematopoietic stem cell transplantation with a new haploid-mismatched donor in relapsed patients after first transplantation: prognostic analysis of 11 cases
publisher	Editorial Office of Journal of Third Military Medical University
publishDate	2021
url	https://doaj.org/article/61403dfc44dd43edb652dc670c73e729
work_keys_str_mv	AT zhupanpan secondhematopoieticstemcelltransplantationwithanewhaploidmismatcheddonorinrelapsedpatientsafterfirsttransplantationprognosticanalysisof11cases AT wuyibo secondhematopoieticstemcelltransplantationwithanewhaploidmismatcheddonorinrelapsedpatientsafterfirsttransplantationprognosticanalysisof11cases AT liulizhen secondhematopoieticstemcelltransplantationwithanewhaploidmismatcheddonorinrelapsedpatientsafterfirsttransplantationprognosticanalysisof11cases AT laixiaoyu secondhematopoieticstemcelltransplantationwithanewhaploidmismatcheddonorinrelapsedpatientsafterfirsttransplantationprognosticanalysisof11cases AT shijimin secondhematopoieticstemcelltransplantationwithanewhaploidmismatcheddonorinrelapsedpatientsafterfirsttransplantationprognosticanalysisof11cases
_version_	1718431233121189888

Second hematopoietic stem cell transplantation with a new haploid-mismatched donor in relapsed patients after first transplantation: prognostic analysis of 11 cases

Ejemplares similares